one-year data from the study will be available this year. Final
results from the trial will be available in the first quarter of 2009.
Newborn Screening for lysosomal storage disorders
-- Based on its belief that early diagnosis can lead to improved outcomes
for patients with lysosomal storage disorders, and as part of its
commitment to serve this community, Genzyme has been working with
researchers to develop technologies useful for newborn screening. Last
month, the company provided a first shipment of reagents for newborn
screening to the Centers for Disease Control and Prevention (CDC) for
worldwide distribution to public health laboratories. Several
laboratories in the United States and around the world have begun the
process of implementing LSD newborn screening programs.
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.
With many established products and services helping patients in nearly
90 countries, Genzyme is a leader in the effort to develop and apply the
most advanced technologies in the life sciences. The company's products and
services are focused on rare inherited disorders, kidney disease,
orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's
commitment to innovation continues today with a substantial development
program focused on these fields, as well as immune disease, infectious
|SOURCE Genzyme Corporation|
Copyright©2008 PR Newswire.
All rights reserved